LB Pharmaceuticals, Inc. (LBRX) Price & Analysis

Compare

10 Followers

LBRX Stock Chart & Stats

$19.12

Market closed

$19.12

Day’s Range― - ―

52-Week Range$13.36 - $23.15

Previous CloseN/A

VolumeN/A

Average Volume (3M)347.37K

Market Cap

N/A

Enterprise ValueN/A

Total Cash (Recent Filing)$72.13M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.52

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding25,299,103

10 Day Avg. Volume178,624

30 Day Avg. Volume347,371

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-0.65

Price to Sales (P/S)0.00

P/FCF Ratio-1.14

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$49.00

Price Target Upside156.28% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Efficacy In Schizophrenia TreatmentThe strong effect size for amisulpride and the highest dose of LB-102 positions it in the top tier for efficacy among schizophrenia agents.

Potential For Additional IndicationsThere is good rationale for additional indications, such as bipolar disorder and major depressive disorder, due to its serotonergic and dopaminergic activity.

Bears Say

Competition From Other AgentsCompeting agents with improved efficacy and safety profiles pose a risk.

Phase 3 Trial RisksKey risks include the potential failure of LB-102 in the Phase 3 trial for schizophrenia.

LB Pharmaceuticals, Inc. News

LB Pharmaceuticals price target raised to $35 from $27 at Stifel

Stifel raised the firm’s price target on LB Pharmaceuticals (LBRX) to $35 from $27 and keeps a Buy...

5d ago

LBRX

LB Pharmaceuticals added to Russell 2000, Russell 3000 indices

LB Pharmaceuticals (LBRX) announced the Company has been included in the Russell 2000 Index and the broad-market Russell...

7d ago

LBRX

LB Pharmaceuticals Expands Lease at One Penn Plaza

LB Pharmaceuticals, Inc. ( ($LBRX) ) has provided an update. On November 10, 2025, LB Pharmaceuticals Inc. amended...

1M ago

LBRX

LB Pharmaceuticals Appoints New Chief Commercial Officer

An announcement from LB Pharmaceuticals, Inc. ( ($LBRX) ) is now available. On November 12, 2025, LB Pharmaceuticals...

1M ago

LBRX

LB Pharmaceuticals appoints Kaya Pai Panandiker as CCO

LB Pharmaceuticals (LBRX) announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer, CCO. Before joining LB...

1M ago

LBRX

NMRA

LB Pharmaceuticals Reports Strong Q3 and Strategic Progress

LB Pharmaceuticals, Inc. ( ($LBRX) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

LBRX

LB Pharmaceuticals reports Q3 EPS (61c) vs ($39.49) last year

“Following our recent initial public offering, we are well-positioned to continue executing on our strategy to advance LB-102...

1M ago

LBRX

LB Pharmaceuticals appoints Rawls as SVP of Regulatory Affairs

LB Pharmaceuticals (LBRX) announced the appointment of James Rawls, Pharm.D., as Senior Vice President, SVP, of Regulatory Affairs....

2M ago

LBRX

Opening Day: Cerebras Systems withdraws IPO filing

Cerebras Systems (CRBS) has withdrawn its IPO filing. In a SEC filing, the company said, in part, “Cerebras...

2M ago

CBK

Buy Rating for LB Pharmaceuticals Driven by Promising LB-102 and Market Potential

LB Pharmaceuticals, Inc. (LBRX) has received a new Buy rating, initiated by Piper Sandler analyst, Yasmeen Rahimi. Yasmeen...

2M ago

LBRX

LB Pharmaceuticals to present posters on Phase 2 NOVA trial of LB-102

LB Pharmaceuticals (LBRX) announced that three posters featuring new and previously reported analyses from its Phase 2 NOVA...

2M ago

LBRX

LB Pharmaceuticals initiated with an Outperform at Leerink

Leerink initiated coverage of LB Pharmaceuticals (LBRX) with an Outperform rating and $34 price target LB-102 is a...

2M ago

LBRX

LB Pharmaceuticals initiated with a Buy at Stifel

Stifel initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $27 price target The firm says...

2M ago

LBRX

LB Pharmaceuticals initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of LB Pharmaceuticals (LBRX) with an Overweight rating and $78 price target The firm...

2M ago

LBRX

LBRX FAQ

What was LB Pharmaceuticals, Inc.’s price range in the past 12 months?

LB Pharmaceuticals, Inc. lowest stock price was $13.36 and its highest was $23.15 in the past 12 months.

What is LB Pharmaceuticals, Inc.’s market cap?

Currently, no data Available

When is LB Pharmaceuticals, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were LB Pharmaceuticals, Inc.’s earnings last quarter?

Currently, no data Available

Is LB Pharmaceuticals, Inc. overvalued?

According to Wall Street analysts LB Pharmaceuticals, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does LB Pharmaceuticals, Inc. pay dividends?

LB Pharmaceuticals, Inc. does not currently pay dividends.

What is LB Pharmaceuticals, Inc.’s EPS estimate?

LB Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does LB Pharmaceuticals, Inc. have?

LB Pharmaceuticals, Inc. has 25,299,103 shares outstanding.

What happened to LB Pharmaceuticals, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of LB Pharmaceuticals, Inc.?

Currently, no hedge funds are holding shares in LBRX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

LB Pharmaceuticals, Inc.

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

LB Pharmaceuticals, Inc. (LBRX) Earnings & Revenues

Historic Earnings Reports

LBRX Stock 12 Month Forecast

Average Price Target

$49.00

▲(156.28% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","79":"$79","30.25":"$30.3","46.5":"$46.5","62.75":"$62.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$78.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$49.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,30.25,46.5,62.75,79],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.43,22.089230769230767,26.748461538461537,31.407692307692308,36.066923076923075,40.72615384615384,45.38538461538461,50.04461538461538,54.70384615384615,59.36307692307692,64.02230769230769,68.68153846153845,73.34076923076923,{"y":78,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.43,19.858461538461537,22.286923076923078,24.715384615384615,27.143846153846155,29.572307692307692,32.00076923076923,34.42923076923077,36.857692307692304,39.286153846153844,41.714615384615385,44.14307692307692,46.57153846153846,{"y":49,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.43,18.704615384615384,19.979230769230767,21.253846153846155,22.52846153846154,23.803076923076922,25.07769230769231,26.352307692307694,27.626923076923077,28.90153846153846,30.176153846153845,31.450769230769232,32.72538461538461,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.8,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1754006400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1756684800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15.76,"date":1759276800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.43,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >